Cardiorenal disease in type 2 diabetes: a paradigm shift in management
Seminar • AstraZeneca
About the CPD course
A thorough presentation developed for UK-based endocrinologists; diabetologists and diabetes-specialist nurses; highlighting the paradigm shift to cardiorenal management in type 2 diabetes mellitus (T2DM). This presentation focuses on clinical outcomes T2DM; heart failure with reduced and preserved ejection fraction, and chronic kidney disease for NICE recommended therapies and key information key information regarding implementation to support healthcare professionals in daily practice to improve patient outcomes.
Send an enquiry
AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines. Our Purpose is to push the boundaries of science to deliver life-changing medicines. We believe the best way we can achieve our Purpose is to put science at the centre of everything we do. Science defines who we are. It is why we come to work every day and is part of our DNA. But this is only half of the story. We know that we do not have all the answers. We want to share ideas because we believe it results in better medicines. We want the way we work to be inclusive, open and collaborative. This approach runs through all that we do.
Want to learn more?
More CPD courses by AstraZeneca
Healthcare & Medical
Cardiorenal protection: a risk-based approach to m...
AstraZeneca
Literature
Healthcare & Medical
Simplifying the management of heart failure across...
AstraZeneca
Seminar
Healthcare & Medical
Are you confident taking a risk-based approach in...
AstraZeneca
Online Course
Healthcare & Medical
Are you considering cardiovascular risk in type 2...
AstraZeneca
Training Video
Get industry-related content straight to your inbox
Thank you for subscribing
By signing up to our site you are agreeing to our privacy policy